When a biotech company announces positive Phase 3 trial results or receives FDA approval, the market reaction is often immediate and substantial. This is not just speculation. These milestones ...

The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in ...

Vertex Technologies participated as an official sponsor of the job fair organized by the Ministry of Communications and ...

Analysts project the U.S. diabetes market will surge past $75 billion by 2031, driven by advanced cell therapies and continuous glucose monitoring systems transforming patient care [3]. Regenerative ...

Resale partners can also leverage industry-leading mobility services including Ensemble, a lightweight EMM, and Samsung Knox for enterprise-grade security. Meanwhile, carriers, MVNOs and national ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY ® (exagamglogene autotemcel) in people ages 5 years and ...

Vertex Pharmaceuticals dominates the cystic fibrosis treatment market and recently has expanded into other therapeutic areas. The biotech predicts full-year 2025 revenue of as much as $12 billion.

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 6.2% in the afternoon session after Morgan Stanley upgraded its rating on the stock to "Overweight" from "Equal-Weight" and ...